(Q37689783)

22 August 2017

title

CCR5 antagonists: the answer to inflammatory disease? (English)

1 reference

22 August 2017

3

Cory M Hogaboam

1 reference

22 August 2017

Traci L Ness

1

1 reference

22 August 2017

Steven L Kunkel

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Therapeutic Patents

22 August 2017

published in

1 reference

22 August 2017

volume

16

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

1051-1065

1 reference

The biology of chemokines and their receptors

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

21 January 2018

Chemokines and disease

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Th1/Th2 cells in inflammatory disease states: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

The case for selection at CCR5-Delta32

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

The evolutionary history of the CCR5-Delta32 HIV-resistance mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Autoantigens act as tissue-specific chemoattractants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Involvement of CCR5 in the passage of Th1-type cells across the blood-retina barrier in experimental autoimmune uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Expression of the C-C chemokine receptor 5 in human kidney diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Infiltration of CD8+ T cells containing RANTES/CCL5+ cytoplasmic granules in actively inflammatory lesions of human chronic gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

The many roles of the class A macrophage scavenger receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Association of CCR5Delta32 with reduced risk of childhood but not adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

The clinical potential of chemokine receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

CC chemokine receptor 5delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

High frequency of CCR5-delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

CCR5 deficiency increases risk of symptomatic West Nile virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Intrapulmonary targeting of RANTES/CCL5-responsive cells prevents chronic fungal asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Regulation of protein function by glycosaminoglycans--as exemplified by chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Amelioration of rat adjuvant-induced arthritis by Met-RANTES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

The effect of the CC chemokine receptor antagonist Met-RANTES on experimental autoimmune uveitis and oral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Differential activation of CC chemokine receptors by AOP-RANTES

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Endocytosis and recycling of the HIV coreceptor CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

TAK-779, a nonpeptide CC chemokine receptor antagonist, protects the brain against focal cerebral ischemia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Synthesis of 1-benzothiepine and 1-benzazepine derivatives as orally active CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Acquired QT interval prolongation and HERG: implications for drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Orally bioavailable competitive CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

CC chemokine receptor 5 and renal-transplant survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.8.1051

10.1517/13543776.16.8.1051

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference